Immunosuppressive regimens in lung transplant recipients

A lung transplant is usually the last resort treatment for lung failure. Since the introduction of cyclosporine A, success rates after solid organ transplantation began to rise, following an incremental curve over the last decade, in which further development of biological agents and newer immunosuppressive agents has continued to improve outcomes after transplantation. Pharmacokinetic and pharmacodynamic properties, as well as efficacy and safety data from clinical trials with immunosuppressive agents and biological agents currently available, are reviewed here.